Tysabri and PML: What Patients Should Know About Risk and Monitoring

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Specialized Pharmaceutical Safety

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). Understanding the timeline of PML development after starting Tysabri is critical for early detection and safety. Building on decades of pharmacovigilance research, this page summarizes the evidence on PML risk factors, FDA warnings, and recommended monitoring strategies.

Bridging General Principles to Tysabri-Specific Risks

Building on the foundational understanding of pharmaceutical safety, we now focus specifically on Tysabri (natalizumab), a monoclonal antibody used primarily in the treatment of multiple sclerosis and Crohn's disease. Its association with progressive multifocal leukoencephalopathy (PML) is a well-documented and serious safety concern, as reflected in the FDA's boxed warning. PML is an opportunistic viral infection of the brain caused by the JC virus (JCV), which typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The FDA has identified three primary risk factors that increase the likelihood of developing PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanistic Pathway Linking Tysabri to PML

The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier. This reduces inflammation in the central nervous system, which is beneficial for treating multiple sclerosis, but it also impairs immune surveillance in the brain. This impairment allows the JC virus, which is latent in many individuals, to reactivate and cause PML. The virus infects oligodendrocytes, leading to demyelination and progressive neurological damage. Clinical presentation of PML includes a range of neurological symptoms that can vary depending on the location of brain lesions. Common symptoms include progressive weakness on one side of the body, clumsiness, visual disturbances, changes in thinking, memory, and personality, and sometimes seizures. Diagnosis is typically confirmed through MRI imaging showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction (PCR). Brain biopsy may be necessary in some cases.

Timeline of Tysabri Exposure and PML Development

The timeline between Tysabri exposure and documented harm from PML can vary. In clinical trials, PML occurred in three patients. Two cases were observed among 1869 patients with multiple sclerosis who were treated for a median of 120 weeks, and these patients had received Tysabri in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The third case occurred after eight doses in one of 1043 patients with Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases illustrate that PML can develop after varying durations of treatment, with risk increasing over time, particularly beyond two years.

FDA Warnings and Risk Mitigation

The adequacy of warnings regarding Tysabri and PML is addressed through the FDA's boxed warning, which is the strongest warning issued by the agency. The warning states that Tysabri increases the risk of PML and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This program is designed to ensure that patients and healthcare providers are informed about the risks and that appropriate monitoring is conducted.

Causation Considerations for Affected Patients

Causation-related considerations for affected patients involve establishing a link between Tysabri use and the development of PML. Given that PML is a rare disease that typically occurs only in immunocompromised individuals, its occurrence in Tysabri-treated patients, who are not otherwise severely immunocompromised, strongly suggests a causal relationship. The FDA's boxed warning explicitly states that Tysabri increases the risk of PML, and the risk factors identified provide a framework for assessing individual patient risk. For patients who develop PML, the timeline of exposure is a critical factor, as the risk increases with longer treatment duration. Patients who have been on Tysabri for more than two years and who are anti-JCV antibody positive are at the highest risk. In summary, the evidence clearly establishes that Tysabri increases the risk of PML, a severe and often fatal brain infection. The FDA has implemented strong warnings and a restricted distribution program to mitigate this risk. Healthcare providers must carefully weigh the benefits of Tysabri against the risk of PML, particularly in patients with identified risk factors, and maintain vigilant monitoring for early signs of the disease.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the FDA's boxed warning for Tysabri regarding PML?

The FDA's boxed warning states that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability. Healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold dosing immediately if such signs appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the primary risk factors for developing PML while on Tysabri?

The FDA has identified three primary risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How does Tysabri cause PML?

Tysabri binds to alpha-4 integrins on immune cells, preventing their migration across the blood-brain barrier. This reduces inflammation but impairs immune surveillance in the brain, allowing the JC virus to reactivate and cause PML. The virus infects oligodendrocytes, leading to demyelination and neurological damage.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.